FDA clears IND application of GT307
“GT307 employs high-fidelity CRISPR/AaCas12MAX gene editing to knock out key immune regulatory genes, designed to address key bottlenecks of conventional TIL therapies, such as TIL exhaustion within the tumor microenvironment and insufficient persistence in vivo,” said Dr. Yarong Liu, CEO, Grit Biotechnologies. “This precise gene-editing strategy, combined with the extensive cell and gene therapy manufacturing experience of our partner uBriGene, allows us to advance next-generation TIL therapies efficiently and safely into the clinic.”
Share:
More News
“From the outset, our goal has been to build a discovery engine that systematically unlocks high-value, challenging targets and delivers first-in-class precision medicines,” said Adam Friedman, M.D., Ph.D., Chief Executive Officer of Antares. “This collaboration lets us scale that engine alongside Novartis’ world-class development capabilities and global reach, so we
“We are very pleased that the iDMC has recommended continuation of the landmark OVATION 3 clinical trial without modification, representing another important validation of the remarkable efficacy and safety data previously reported and further indicating the potential for IMNN-001 to represent a historic advance in the treatment of ovarian cancer,”
“VS-7375 has demonstrated anti-tumor activity across multiple dose levels and tumor types, encouraging signals from rational combination strategies, and a favorable safety profile that improves meaningfully beyond the first treatment cycle, underscoring its potential to be not only the best-in-class oral KRAS G12D inhibitor, but also the preferred treatment option
“We are pleased that the FDA has demonstrated urgency in reconsidering the RP1 BLA with an expeditious action date in recognition of the significant unmet need for advanced melanoma patients and support from the broader melanoma community,” said Sushil Patel, Ph.D., CEO of Replimune. “We look forward to a productive